Valuation dashboard for Rhythm Pharmaceuticals, Inc. (RYTM) with P/E N/A, P/B 29.61, EV/EBITDA -34.1 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R).
Analysis Summary
Trailing-twelve-month margins: gross margin 88.2%, operating margin -66.7%, net margin -69.0%.
At $86.44 (closing price, November 3, 2026), RYTM has negative trailing earnings (P/E not meaningful) and an ROE of -83.68%. Market capitalisation stands at $6.0B.
Balance sheet quality for RYTM: debt-to-equity ratio of 0.02, current ratio of 2.78 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 29.61 |
| EV / EBITDA | -34.1 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | $6.0B | 29.61 | -83.7% | |
| BMRN | BioMarin Pharmaceutical Inc. | $10.8B | 1.72 | -0.3% | |
| BLTE | Belite Bio, Inc | $6.1B | 7.93 | -15.6% | |
| VKTX | Viking Therapeutics, Inc. | $3.3B | 5.23 | -117.3% | |
| MBX | MBX Biosciences, Inc. Common Stock | $2.6B | 6.41 | -26.0% | |
| SEPN | Septerna Inc | $2.0B | 5.09 | -6.3% |
Price
| Price | $86.44 (closing price, November 3, 2026) |
| Market Cap | $6.0B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -83.68% |
| Return on Invested Capital | -63.91% |
| Return on Assets | -43.74% |
| Gross Margin | 88.23% |
| Operating Margin | -66.70% |
| Net Margin | -69.03% |
Related companies: BMRN · BLTE · VKTX · MBX · SEPN
Explore sector: Healthcare · Biotechnology
More sections of RYTM: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks